Literature DB >> 29876617

FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients.

E Incerti1, S Broggi2, A Fodor3, M Cuzzocrea4, A M Samanes Gajate1, P Mapelli1,5, C Fiorino2, I Dell'Oca3, M Pasetti3, M Cattaneo2, R Calandrino2, L Gianolli1, N Di Muzio3, Maria Picchio6,7.   

Abstract

PURPOSE: The value of FDG PET-derived parameters in predicting overall survival (OS), local relapse-free survival (LRFS) and distant relapse-free survival (DRFS) in treated patients with malignant pleural mesothelioma (MPM) was evaluated.
METHODS: This retrospective evaluation included 55 MPM patients treated between March 2006 and February 2015 with FDG PET/CT-guided salvage helical tomotherapy (HTT) after previous surgery plus chemotherapy. Univariate Cox regression analysis was performed to assess the impact of the following FDG PET-derived parameters: biological target volume (BTV), mean and maximum standardized uptake values (SUVmean/max), metabolic tumour volume (MTV) and total lesion glycolysis (TLG), measured using different uptake thresholds (40%, 50% and 60%). Logistic regression was then performed to identify the best FDG PET-derived parameters for selecting patients with poorer survival.
RESULTS: The median OS was 9.1 months (range 0.0 - 69.6 months) after the end of HTT; 54/55 patients were dead at the last follow-up. BTV and TLG40, TLG50 and TLG60 were the most significant predictors of OS (p < 0.005). The median OS was 4.8 months in patients with MTV60 >5 cm3 and TLG40 >334.4, compared with 13.8 months and 16.1 months in patients with smaller values, respectively. The median LRFS and DRFS were 6.2 months (range 1.2 - 39.4 months) and 6.5 months (0.0 - 66.4 months), respectively. TLG40, TLG50 and TLG60 were significantly correlated with LRFS (p < 0.015). Median DRFS was 6.4 months in patients with MTV40 >39.6 cm3 and 6.2 months in patients with TLG40 >334.4, compared with 17 months and 18.8 months in patients with smaller values. BTV, TLG40 and MTV40 were also found to be good predictors in patients with poor OS/LRFS/DRFS (median survival times less than the median values).
CONCLUSION: FDG PET-derived parameters effectively discriminated patients with a poor prognosis and may be helpful in the selection of MPM patients for salvage HTT.

Entities:  

Keywords:  FDG PET/CT; Helical tomotherapy; MTV; Malignant pleural mesothelioma; Survival; TLG

Mesh:

Substances:

Year:  2018        PMID: 29876617     DOI: 10.1007/s00259-018-4056-6

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  35 in total

1.  Prognostic value of FDG PET imaging in malignant pleural mesothelioma.

Authors:  D C Ng; S F Hain; M J O'Doherty; J Dussek
Journal:  J Nucl Med       Date:  2000-08       Impact factor: 10.057

Review 2.  The role of radiation therapy in malignant pleural mesothelioma: a systematic review.

Authors:  Yee C Ung; Edward Yu; Conrad Falkson; Adam E Haynes; Denise Stys-Norman; William K Evans
Journal:  Radiother Oncol       Date:  2006-07-03       Impact factor: 6.280

3.  Role of postoperative radiotherapy in the management of malignant pleural mesothelioma : A propensity score matching of the SEER database.

Authors:  Omar Abdel-Rahman
Journal:  Strahlenther Onkol       Date:  2017-01-02       Impact factor: 3.621

Review 4.  Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies.

Authors:  Andrew R Haas; Daniel H Sterman
Journal:  Clin Chest Med       Date:  2013-01-17       Impact factor: 2.878

5.  Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.

Authors:  D B Schneider; C Clary-Macy; S Challa; K C Sasse; S H Merrick; R Hawkins; G Caputo; D Jablons
Journal:  J Thorac Cardiovasc Surg       Date:  2000-07       Impact factor: 5.209

Review 6.  Morphologic and functional imaging of malignant pleural mesothelioma.

Authors:  Masaki Yamamuro; Victor H Gerbaudo; Ritu R Gill; Francine L Jacobson; David J Sugarbaker; Hiroto Hatabu
Journal:  Eur J Radiol       Date:  2007-10-22       Impact factor: 3.528

7.  Stereotactic intensity-modulated radiation therapy (IMRT) and inverse treatment planning for advanced pleural mesothelioma. Feasibility and initial results.

Authors:  Marc W Münter; Simeon Nill; Christoph Thilmann; Holger Hof; Angelika Höss; Peter Häring; Mike Partridge; Christian Manegold; Michael Wannenmacher; Jürgen Debus
Journal:  Strahlenther Onkol       Date:  2003-08       Impact factor: 3.621

8.  Tomotherapy PET-guided dose escalation: A dosimetric feasibility study for patients with malignant pleural mesothelioma.

Authors:  Angelo Maggio; Claudia Cutaia; Amalia Di Dia; Sara Bresciani; Anna Miranti; Matteo Poli; Elena Del Mastro; Elisabetta Garibaldi; Pietro Gabriele; Michele Stasi
Journal:  Strahlenther Onkol       Date:  2015-10-09       Impact factor: 3.621

9.  Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.

Authors:  Victor H Gerbaudo; David J Sugarbaker; Scott Britz-Cunningham; Marcelo F Di Carli; Charles Mauceri; S Ted Treves
Journal:  J Nucl Med       Date:  2002-09       Impact factor: 10.057

10.  The European mesothelioma epidemic.

Authors:  J Peto; A Decarli; C La Vecchia; F Levi; E Negri
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  1 in total

Review 1.  The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review.

Authors:  Silvia Taralli; Romina Grazia Giancipoli; Carmelo Caldarella; Valentina Scolozzi; Sara Ricciardi; Giuseppe Cardillo; Maria Lucia Calcagni
Journal:  J Clin Med       Date:  2021-12-22       Impact factor: 4.241

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.